Acitretin 17.5 MG Oral Capsule — RxCUI 894859
RxNorm drug concept · Semantic clinical drug
RxCUI 894859
Semantic clinical drug · SCD
● Current RxNorm concept 20 FDA products
20 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI894859
Official nameAcitretin 17.5 MG Oral Capsule
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped20
Package NDCs mapped20
Reported Medicaid activity (SDUD)3,214 prescriptions · 24 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Acitretin: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Acitretin is a type of medicine called a retinoid — it's related to vitamin A and works to help control the way your skin cells grow and shed. It's used for severe psoriasis when o...
- What exactly is acitretin and why did my doctor prescribe it for my psoriasis?
- Taking acitretin with your main meal makes a real difference — food helps your body absorb the medication much better. Your prescriber chose your dose based on studies where it was...
- This is one of the most important things to understand about acitretin. It is known to cause very serious, life-threatening birth defects, and this risk doesn't go away the moment...
🕸️ Concept Web — How Acitretin 17.5 MG Oral Capsule Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Acitretin 17.5 MG Oral Capsule
RxCUI 894859 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Acitretin
16818IN
-
Acitretin
-
Dose forms 6
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Acitretin Oral Capsule
370533SCDF -
Acitretin Oral Product
1153162SCDG -
Acitretin Pill
1153163SCDG -
Oral Capsule
316965DF -
Oral Product
1151131DFG -
Pill
1151133DFG
-
Acitretin Oral Capsule
-
Clinical & branded drugs 1
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Acitretin 17.5 MG
894858SCDC
-
Acitretin 17.5 MG
Showing up to 8 concepts per family — 8 of 8 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Acitretin 17.5 MG
SCDC · 894858 -
Acitretin Oral Capsule
SCDF · 370533 -
Acitretin Oral Product
SCDG · 1153162 -
Acitretin Pill
SCDG · 1153163
📦 FDA Products & Package NDCs
20 products · 20 package NDCs
20 package NDCs map to RxCUI 894859 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 00093-1135-56 | 30 CAPSULE in 1 BOTTLE (0093-1135-56) | Acitretin | Teva Pharmaceuticals USA, Inc. | 2013-07-19 |
| 00093-1136-56 | 30 CAPSULE in 1 BOTTLE (0093-1136-56) | Acitretin | Teva Pharmaceuticals USA, Inc. | 2013-07-19 |
| 00093-1138-56 | 30 CAPSULE in 1 BOTTLE (0093-1138-56) | Acitretin | Teva Pharmaceuticals USA, Inc. | 2013-07-19 |
| 00115-1750-08 | 30 CAPSULE in 1 BOTTLE, PLASTIC (0115-1750-08) | Acitretin | Amneal Pharmaceuticals of New York LLC | 2016-01-04 |
| 00115-1751-08 | 30 CAPSULE in 1 BOTTLE, PLASTIC (0115-1751-08) | Acitretin | Amneal Pharmaceuticals of New York LLC | 2016-01-04 |
| 00115-1752-08 | 30 CAPSULE in 1 BOTTLE, PLASTIC (0115-1752-08) | Acitretin | Amneal Pharmaceuticals of New York LLC | 2016-01-04 |
| 00115-1753-08 | 30 CAPSULE in 1 BOTTLE, PLASTIC (0115-1753-08) | Acitretin | Amneal Pharmaceuticals of New York LLC | 2016-01-04 |
| 42291-0086-30 | 30 CAPSULE in 1 BOTTLE (42291-086-30) | ACITRETIN | AvKARE | 2017-10-11 |
| 42291-0087-30 | 30 CAPSULE in 1 BOTTLE (42291-087-30) | ACITRETIN | AvKARE | 2017-10-11 |
| 42291-0088-30 | 30 CAPSULE in 1 BOTTLE (42291-088-30) | ACITRETIN | AvKARE | 2017-10-11 |
| 42794-0080-08 | 30 CAPSULE in 1 BOTTLE (42794-080-08) | ACITRETIN | Sigmapharm Laboratories, LLC | 2015-09-16 |
| 42794-0081-08 | 30 CAPSULE in 1 BOTTLE (42794-081-08) | ACITRETIN | Sigmapharm Laboratories, LLC | 2015-09-16 |
| 42794-0083-08 | 30 CAPSULE in 1 BOTTLE (42794-083-08) | ACITRETIN | Sigmapharm Laboratories, LLC | 2015-09-16 |
| 46708-0741-30 | 30 CAPSULE in 1 BOTTLE (46708-741-30) | Acitretin | Alembic Pharmaceuticals Limited | 2024-08-08 |
| 46708-0742-30 | 30 CAPSULE in 1 BOTTLE (46708-742-30) | Acitretin | Alembic Pharmaceuticals Limited | 2024-08-08 |
| 46708-0743-30 | 30 CAPSULE in 1 BOTTLE (46708-743-30) | Acitretin | Alembic Pharmaceuticals Limited | 2024-08-08 |
| 62332-0741-30 | 30 CAPSULE in 1 BOTTLE (62332-741-30) | Acitretin | Alembic Pharmaceuticals Inc. | 2024-08-08 |
| 62332-0742-30 | 30 CAPSULE in 1 BOTTLE (62332-742-30) | Acitretin | Alembic Pharmaceuticals Inc. | 2024-08-08 |
| 62332-0743-30 | 30 CAPSULE in 1 BOTTLE (62332-743-30) | Acitretin | Alembic Pharmaceuticals Inc. | 2024-08-08 |
| 72162-2224-03 | 30 CAPSULE in 1 BOTTLE (72162-2224-3) | ACITRETIN | Bryant Ranch Prepack | 2024-01-26 |
Observed labelers:
Amneal Pharmaceuticals of New York LLC (4) ·
Alembic Pharmaceuticals Inc. (3) ·
Alembic Pharmaceuticals Limited (3) ·
AvKARE (3) ·
Sigmapharm Laboratories, LLC (3) ·
Teva Pharmaceuticals USA, Inc. (3)
· +1 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.